Ziyintoni Isifo Sokugonya?

Xa abaninzi abantu beva igama lokugonya, bacinga ngendlela yokukhusela izifo. Nangona kunjalo, izitofu zonyango azinasetyenziselwa ukuthintela. Kunoko, basebenzisa njengendlela yokonyango. Njengokugonywa rhoqo, iigciwane zonyango zisetyenziselwa ukuvuselela i-immune system ukujolisa intsholongwane okanye uhlobo lwesitrha esifilekileyo - njengengqamzana yesifo somhlaza.

Ngamanye amagama, banceda ukufundisa umzimba ukuba wenze njani umsebenzi ongcono wokuzikhusela ukuze ulawule, okanye ulahlekise, kunzima ukunyanga imeko.

Ininzi yeengxoxo zonyango zonyango zibhekiselele kwizonyango ezijoliswe kumdlavuza . Nangona kunjalo, ininzi yabaphandi bayasebenza ekuphuhliseni iigciwane zonyango ezinokukwazi ukulawula ii-STD zentsholongwane kunye neengxaki zabo. Ngokomzekelo, akuyiyo yonke uphando oluqhubekayo lokugonya igciwane lesandulela ngculaza olufuna indlela yokukhusela i- HIV . Ezinye izazinzulu zisebenzela ekuphuhliseni isitofu sonyango lokuncedisa ukufumana uncedo kwizigulane ezichaphazelekayo zigcina imithwalo engaphantsi kwintsholongwane . Oku kufuneka ukuba kwenzeke, njengoko izazinzulu ziyazi ukuba ezinye izigulane ezinegciwane zide zithuba ezingezo-inkqubelayo imizimba yabo enokukwazi ukugcina izifo zabo zilawulwa yi-HIV.

Enye i-STD yentsholongwane ejoliswe ngabaphengululi wokugonywa yi- papillomavirus yabantu (HPV).

Izitofu zokuthintela ezibini zisekuthengiseni , kodwa izigidi zamadoda nabasetyhini bahlaselwe yi-HPV ngaphambi kokuba ezo zitofu zifumaneke, kwaye baninzi abasulelekileyo ngosuku. Ngako-ke, izazinzulu zifuna iindlela zokunceda imizimba yabasetyhini ibe nomsebenzi ongcono wokususa ezo zifo ukukhusela ukuqhubela phambili emdlalweni wesibeleko somlomo wesibeleko - okanye nayiphi enye i- HPV yomdlavuza ingabangela kubini abasetyhini namadoda .

Olu phando lugqithisa ngophando lweklinikhi ejoliswe kumhlaza, njengokuba ezinye izitofu ezisebenza kule ndawo zilandela izicubu ezibangelwa yi-HPV kunokuba ususulele usulelo lwe-HIV.

Ngaphezu koko, nangona abanye abantu becinga , izazinzulu zisebenza ngokuzimeleyo kwizigulane zonyango kunye nezithintelo ze- herpes . Ngelishwa, ukuya kutsho kakhulu uphando aluzange uphumelele. Sekunjalo, yinjongo enamandla kwaye ebalulekileyo, kwaye ngokuqinisekileyo abantu bazama ukuza neendlela ezingcono zokunyanga i-herpes.

Ekugqibeleni, i- hepatitis C isoloko ibalulekileyo ekujoliswe kuyo ekuphuculweni kwegciwane, nangona ulindelo alukho phezulu. Esinye sezizathu zokuba kutheni i-hepatitis C inzima kakhulu kukuba i-immune system ngokubanzi yenza umsebenzi omuhle wokulwa nayo. Ngethamsanqa, ukuphuhliswa kokusebenza ngokuthe ngqo kwi-antitivirals okwangoku okwenza ukufuna isitofu kuvezwe ngokungxamisekileyo, kodwa abantu abaninzi baya kuvuya xa bekukhuselwe njenge- hepatitis A kunye ne-B - apho iindawo zokukhusela ezikhuselekileyo zifumanekile. .

Imithombo:

UDiniz, MO et al. (2013) Ukuphucula iziphumo zonyango ezinikezelwe yicandelo lokulinga lokugonywa kwe-DNA ekujoliswe kuzo izidumbu ezibangelwa yi-papillomavirus. Hum Gene Ther. 24 (10): 861-70.

Johnston, C., Koelle, DM, Wald, A. (2013) Isimo samanje kunye nethuba lokuphuhliswa kwe-HSV. Igciwane. Ubungqina obulungisiweyo obuFinyelelekileyo kwi-intanethi ngoNovemba 6, 2013.

Liang, TJ. (2013) Inkqubela yangoku ekuphuhlisweni kwegciwane legciwane le-hepatitis C. Nat Med. 19 (7): 869-78.

UMorrow, iPhalamende, uYan, J., uSardesai, NY (2013) Iigciwane le-papillomavirus zonyango zokugonywa: ukujoliswa kwee-antigens zentsholongwane njenge-immunotherapy ngenxa yesifo esichengileyo kunye nomhlaza. Iingcaphephe zoVavanyo. 12 (3): 271-83.

Rodriguez, B. et al. (2013) Ukhuseleko, ukunyanzeliswa, kunye nokungahambi kakuhle kweeDerms of Derms of DermaVir, i-Candidate Therapeutic HIV vaccine, kwi-HIV-Infected Patients Receiving Antiretroviral Therapy: Iziphumo ze-ACTG 5176. I-Acquir Immune Defic Defic Syndr. 64 (4): 351-9.

Zong, J. et al. (2013) i-HSP70 kwaye iguqulwe i-HPV 16 E7 yefusion yefusion ngaphandle kokungqiniswa kwesigxina sokulandelelana kwegciwane le-peptide njengegciwane lokugonywa kwe-tumor. I-Oncol Rep 30 (6): 3020-6.